RCT: Final analysis of 3 vs. 6 months of adjuvant Oxaliplatin and Fluoropyrimidine-based therapy in patients with Stage III colon cancer.

Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial – Journal of Clinical Oncology

Commentaries on Twitter

In Asian (Japan) patients with stage III colon cancer, 3 months of CAPOX therapy is an appropriate adjuvant treatment option in patients with low-risk disease- ACHIEVE trialhttps://t.co/BzjepOoal8

— K Pavithran (@drkpavithran) May 6, 2022